Issued: London, UK
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Charles Bancroft will join the Board of the Company as a Non-Executive Director on 1 May 2020.
Charlie has recently retired from a successful career at Bristol Myers Squibb (BMS) where he held a number of leadership roles in commercial, strategy and finance. Beginning his career at BMS in 1984, he held positions of increasing responsibility within the finance organisation and had commercial operational responsibility for Latin America, Middle East, Africa, Canada, Japan and several Pacific Rim countries. He was appointed Chief Financial Officer in 2010, Chief Financial Officer and Executive Vice President, Global Business Operations in 2016 and Executive Vice President and Head of Integration and Strategy & Business Development in 2019. Charlie successfully steered BMS through a period of strategic transformation, including the recent $74bn acquisition of Celgene.
Charlie served as a member of the Board of Colgate-Palmolive Company from 2017 until March 2020.
On joining the Board Charlie will become a member of the Audit & Risk Committee. He will succeed Judy Lewent as Chair of this Committee following approval of GSK’s 2020 Annual Report in Q1 of 2021.
Commenting on the appointment, Sir Jonathan Symonds, Chairman of GSK said: “I am delighted Charlie is joining the GSK Board and has agreed to succeed Judy in 2021 as Chair of our Audit & Risk Committee. He brings a wealth of financial and management experience in global biopharma which will be invaluable to the Board in the coming years as it oversees the delivery of GSK’s strategy, including the separation of the Group and the creation of two outstanding new companies.”
- The appointment of Charles Bancroft was made by the Board on the recommendation of the Nominations Committee.
- The Board determined that Mr Bancroft is an independent Non-Executive Director on appointment in accordance with the UK Corporate Governance Code (the Code). He has also been designated as having recent and relevant financial experience for the purposes of the Code and as an audit committee financial expert as defined in rules promulgated under the Sarbanes-Oxley Act of 2002.
- He will receive the standard basic fee for a Non-Executive Director of £95,000 per annum and when he succeeds Ms Lewent as Chair of the Audit & Risk Committee, he will receive the supplemental fee of £80,000 per annum. He will be required to invest at least 25% of his fees in GSK shares that should be held until he retires from the Board.
- Membership of other Committees will be determined in due course.
- Mr Bancroft does not have a service contract. He has a letter of appointment which may be viewed by contacting the Company Secretary at the Company’s registered office.
- There are no additional details to disclose in respect of Mr Bancroft’s appointment under Listing Rule 9.6.13R.
- From 1 May 2020 the Board of GSK will comprise:
|Sir Jonathan Symonds||Non-Executive Chairman|
|Emma Walmsley||Chief Executive Officer|
|Iain Mackay||Chief Financial Officer|
|Dr Hal Barron||Chief Scientific Officer and President, R&D|
|Vindi Banga||Senior Independent Non-Executive Director|
|Charles Bancroft||Independent Non-Executive Director|
|Dr Vivienne Cox||Independent Non-Executive Director|
|Lynn Elsenhans||Independent Non-Executive Director|
|Dr Jesse Goodman||Independent Non-Executive Director|
|Dr Laurie Glimcher||Independent Non-Executive Director|
|Judy Lewent||Independent Non-Executive Director|
|Urs Rohner||Independent Non-Executive Director|
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D ‘Principal risks and uncertainties’ in the company’s Annual Report on Form 20-F for 2019.